SHUKRA PHARMACEUTICALS
|
SHUKRA PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.50 | 0.22 | 16.94 | 11.26 | 4.79 |
| CEPS(Rs) | 0.58 | 0.29 | 0.47 | 0.40 | 0.08 |
| DPS(Rs) | 0.01 | 0.01 | 1.00 | 0.50 | 0.50 |
| Book NAV/Share(Rs) | 1.93 | 1.44 | 52.67 | 64.63 | 104.43 |
| Tax Rate(%) | 23.37 | 28.20 | 6.77 | 0.79 | 26.26 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 50.76 | 39.06 | 26.02 | 9.12 | 14.09 |
| EBIT Margin(%) | 52.78 | 42.75 | 27.05 | 8.03 | 6.37 |
| Pre Tax Margin(%) | 50.74 | 40.93 | 26.66 | 7.55 | 4.97 |
| PAT Margin (%) | 38.88 | 29.38 | 24.86 | 7.49 | 3.66 |
| Cash Profit Margin (%) | 44.95 | 38.60 | 27.61 | 10.61 | 11.78 |
| Performance Ratios | |||||
| ROA(%) | 21.60 | 11.63 | 24.26 | 8.01 | 2.12 |
| ROE(%) | 29.94 | 15.90 | 44.70 | 21.16 | 4.70 |
| ROCE(%) | 36.98 | 21.80 | 44.24 | 18.85 | 5.79 |
| Asset Turnover(x) | 0.56 | 0.40 | 0.98 | 1.07 | 0.58 |
| Sales/Fixed Asset(x) | 1.22 | 0.77 | 1.85 | 1.58 | 0.60 |
| Working Capital/Sales(x) | 0.93 | 0.68 | 1.77 | 5.57 | 5.86 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.82 | 1.29 | 0.54 | 0.63 | 1.67 |
| Receivable days | 102.07 | 186.38 | 133.86 | 116.60 | 152.77 |
| Inventory Days | 76.78 | 68.70 | 13.39 | 22.06 | 50.20 |
| Payable days | 222.02 | 369.82 | 167.55 | 170.00 | 245.53 |
| Valuation Parameters | |||||
| PER(x) | 60.26 | 99.91 | 0.48 | 1.04 | 2.62 |
| PCE(x) | 52.12 | 76.05 | 17.36 | 2.94 | 3.92 |
| Price/Book(x) | 15.73 | 15.23 | 6.20 | 0.73 | 0.58 |
| Yield(%) | 0.03 | 0.05 | 0.31 | 1.07 | 0.83 |
| EV/Net Sales(x) | 23.41 | 29.12 | 4.70 | 0.33 | 0.61 |
| EV/Core EBITDA(x) | 39.79 | 56.02 | 15.78 | 2.97 | 4.23 |
| EV/EBIT(x) | 44.36 | 68.11 | 17.38 | 4.12 | 9.61 |
| EV/CE(x) | 14.00 | 14.16 | 5.77 | 0.64 | 0.64 |
| M Cap / Sales | 23.43 | 29.36 | 4.79 | 0.31 | 0.46 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 74.01 | -56.30 | 26.75 | 187.19 | 82.97 |
| Core EBITDA Growth(%) | 97.03 | -23.77 | 238.70 | 121.12 | 64.81 |
| EBIT Growth(%) | 114.81 | -30.92 | 327.07 | 261.99 | 895.12 |
| PAT Growth(%) | 130.26 | -48.35 | 320.68 | 486.99 | 299.10 |
| EPS Growth(%) | 130.22 | -98.71 | 50.47 | 134.80 | 299.10 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.06 | 0.07 | 0.05 | 0.20 | 0.21 |
| Current Ratio(x) | 3.63 | 3.78 | 3.97 | 1.25 | 1.28 |
| Quick Ratio(x) | 3.03 | 3.21 | 3.81 | 1.17 | 0.96 |
| Interest Cover(x) | 25.94 | 23.42 | 70.77 | 16.82 | 4.55 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.10 | 0.36 |
Compare Financial Ratios of peers of SHUKRA PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SHUKRA PHARMACEUTICALS | ₹2,462.7 Cr | 1.1% | 26.3% | 78.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹444,717.0 Cr | -0.8% | -2.5% | 11.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹255,115.0 Cr | 1.9% | 6.6% | 55.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,613.0 Cr | 0.3% | 2% | 35.9% | Stock Analytics | |
| CIPLA | ₹112,876.0 Cr | 0.9% | -0.8% | -10.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,395.0 Cr | 0.1% | 1.4% | -9.3% | Stock Analytics | |
SHUKRA PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SHUKRA PHARMACEUTICALS | 1.1% |
26.3% |
78.3% |
| SENSEX | -0.5% |
-4.8% |
-11% |
You may also like the below Video Courses
